ShareValue scores for ONESOURCE.NSE: Valuation 35, Quality 38, Growth 33, Health 43.

ONESOURCE.NSE
NSE

ONESOURCE SPECIALTY PHARMA LTD

₹1,557.10(+0.22%)
Loading chart...
Sentiment

Verdicts

Rating

Trap Risk

Return

-7% to 10%
Valuation
35
Overvalued
Price vs Value
Quality
38
Weak
Business Strength
Growth
33
Weak
Revenue & Earnings
Health
43
Moderate
Financial Stability
Momentum
62
Bullish
Price Trend

Company Details

About

OneSource Specialty Pharma Limited, a biopharmaceutical company, engages in the research, development, manufacture, and commercialization of biological drug products in various injectable formats in India, Ireland, the United States, and internationally. The company provides end-to-end contract development and manufacturing operations (CDMO) services across various phases of preclinical and clinical development and commercial supply of biologics. It also offers drug-devices, including prefilled syringes, dial and push variable and fixed dose pen injectors, pull push fixed dose pens, and autoinjectors; sterile injectables; soft gelatin capsules; and biologics solutions for microbial and mammalian cell line biopharmaceuticals, cell and gene therapy, and RNA products. The company was formerly known as Stelis Biopharma Limited and changed its name to OneSource Specialty Pharma Limited in February 2024. OneSource Specialty Pharma Limited was incorporated in 2007 and is based in Bengaluru, India.

Score Analysis

AI Investment Thesis

Data as of:Aug 7, 2026
|
Last calculated:Aug 7, 2026